Clearside Biomedical (CLSD) to Release Earnings on Thursday

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $6.35 million during the quarter, compared to analyst estimates of $3.40 million. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Stock Performance

Shares of CLSD traded up $0.05 during trading hours on Thursday, hitting $1.32. 185,977 shares of the stock were exchanged, compared to its average volume of 325,290. Clearside Biomedical has a 12-month low of $0.65 and a 12-month high of $2.12. The company has a market cap of $98.63 million, a price-to-earnings ratio of -2.49 and a beta of 2.35. The stock's 50-day moving average price is $1.45 and its two-hundred day moving average price is $1.23.

Insider Activity

In related news, insider Ngai Hang Victor Chong purchased 30,000 shares of the business's stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average price of $1.60 per share, for a total transaction of $48,000.00. Following the acquisition, the insider now directly owns 30,000 shares of the company's stock, valued at approximately $48,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Bradford T. Whitmore acquired 444,444 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average cost of $1.35 per share, for a total transaction of $599,999.40. Following the transaction, the insider now directly owns 4,495,034 shares of the company's stock, valued at approximately $6,068,295.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ngai Hang Victor Chong purchased 30,000 shares of the business's stock in a transaction dated Wednesday, March 20th. The stock was bought at an average cost of $1.60 per share, with a total value of $48,000.00. Following the completion of the acquisition, the insider now owns 30,000 shares of the company's stock, valued at $48,000. The disclosure for this purchase can be found here. Insiders acquired 481,154 shares of company stock valued at $656,387 in the last three months. 9.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on CLSD. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 price objective on shares of Clearside Biomedical in a research note on Wednesday, March 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 price target on shares of Clearside Biomedical in a report on Thursday, April 11th. HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Thursday, March 14th. Wedbush reissued an "outperform" rating and issued a $4.00 price objective (down from $5.00) on shares of Clearside Biomedical in a report on Wednesday, March 13th. Finally, StockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Saturday, February 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $4.75.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.